Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?

Documenti analoghi

• Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?
  di: Kartik Sehgal, et al.
  Pubblicazione: (2020-05-01)
• Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR‐G719A and Other Uncommon EGFR Mutations
  di: Sehgal, Kartik, et al.
  Pubblicazione: (2020)
• The Rapidly Evolving Landscape of Biomarker Testing in Non-Small Cell Lung Cancer
  di: VanderLaan, Paul A., et al.
  Pubblicazione: (2020)
• Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic?
  di: Sehgal, Kartik, et al.
  Pubblicazione: (2020)
• PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non–small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option?
  di: Torous, Vanda F., et al.
  Pubblicazione: (2018)